Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug
By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said China’s National Medical Products Administration (NMPA) approved the use of lisaftoclax for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The authorization makes lisaftoclax the first inhibitor of...